Cadrenal Therapeutics to Showcase Phase 3-Ready CAD-1005 and Novel 12-LOX Platform at BIO International Convention 2026 Partnering Event
Cadrenal Therapeutics will showcase its pipeline at the BIO International Convention 2026 Partnering Event in San Diego, June 22–25. The company is seeking partnerships for CAD-1005, a Phase 3-ready 12-LOX inhibitor for HIT, and tecarfarin, a late-stage anticoagulant with FDA Orphan Drug and Fast Track designations.
Key figures
- Peak annual revenue potential
- $2 billion
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.